Biopharma Healthcare Provider Leads 
pharmaphorum
DECEMBER 18, 2022
However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcare providers (HCPs) as consumers. This, once again, leads to abandonment caused by patient out-of-pocket costs as a critical driver in non-adherence.
PM360
AUGUST 24, 2023
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarify Health
MAY 19, 2020
Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., sales, medical science liaisons, etc.).
Legacy MEDSearch
MAY 19, 2023
Through this collaboration, healthcare providers are able to access clinically relevant heart rhythm analyses and actionable reports via PaceMateLIVE to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and drive improvements to patient care and clinical outcomes.
Clarivate
FEBRUARY 28, 2023
Degeneration of the retinal ganglion cells causes rapidly progressing vision loss, leading to permanent (non-painful) blindness within a year. The Incidence and Prevalence Database (IPD) , a Cortellis solution, provides information on LHON prevalence and primary mutations, morbidity and mortality rates. 2017.02.001 [3] Filatov A et al.
PM360
APRIL 22, 2024
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
PM360
NOVEMBER 12, 2024
One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. healthcare system over $800 billion annually. From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years.
Expert insights. Personalized for you.
98 
Let's personalize your content